KRAS and colorectal neoplasm: CXCL8 signaling is also known to be promoted downstream of KRas mutations [11,12], suggesting that enrichment of lung, pancreatic or colorectal tumors harboring KRas mutations may be more responsive to anti-CXCL8 therapeutics.